A Phase III Trial of Inebilizumab in Generalized Myasthenia Gravis

In this Phase III, double-blind, randomized, placebo-controlled trial, scientists enrolled participants with myasthenia gravis who had anti–acetylcholine receptor antibodies or anti–muscle-specific kinase antibodies.